EU panel supports approval of 4 new drugs

04/29/2013 | Reuters

The European Medicines Agency's Committee for Medicinal Products for Human Use endorsed the approval of Roche Holding and Curis' advanced basal cell carcinoma drug Erivedge as well as Astellas Pharma and Medivation's prostate cancer treatment Xtandi. Genzyme's MAC1, a tissue-engineered treatment for cartilage defects, and Vivus' erectile dysfunction drug Spedra also received approval recommendations from the panel.

View Full Article in:

Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD